Acadia Pharmaceuticals (ACAD) Receivables (2016 - 2026)

Acadia Pharmaceuticals' Receivables history runs 11 years deep, the most recent figure standing at $148.4 million for Q1 2026.

• In Q1 2026, Receivables rose 30.49% year-over-year to $148.4 million; the TTM figure through Mar 2026 stood at $148.4 million (up 30.49% YoY), while the FY2025 annual figure was $148.2 million, up 41.58% from the prior year.
• Receivables for Q1 2026 stood at $148.4 million, roughly flat from $148.2 million in the prior quarter.
• The five-year high for Receivables was $148.4 million in Q1 2026, with the low at $56.1 million in Q3 2022.
• The 5-year median for Receivables is $102.4 million (2023), against an average of $99.9 million.
• The sharpest annual moves came in 2022 and 2023: Receivables fell 8.97% in 2022, then surged 68.4% in 2023.
• Acadia Pharmaceuticals' Receivables stood at $63.1 million in 2022, then soared by 62.25% to $102.4 million in 2023, then grew by 2.29% to $104.7 million in 2024, then jumped by 41.58% to $148.2 million in 2025, then gained by 0.1% to $148.4 million in 2026.
• Business Quant data shows ACAD's Receivables at $148.4 million in Q1 2026, $148.2 million in Q4 2025, and $139.4 million in Q3 2025.